Evidence map›Paper›PMID 41014460›Full record

ReviewInflammopharmacology2025

Targeting the awry Aβ pathway in Alzheimer's disease: hype and hurdles.

Hayder M Al-Kuraishy, Ghassan M Sulaiman, Ali I Al-Gareeb, Hamdoon A Mohammed, Ali K Albuhadily, Mosleh M Abomughaid

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hayder M Al-KuraishyDepartment of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Ghassan M SulaimanDepartment of Applied Sciences, University of Technology, Baghdad, 10066, Iraq. ghassan.m.sulaiman@uotechnology.edu.iq.ORCID http://orcid.org/0000-0001-6388-3849
Ali I Al-GareebJabir Ibn Hayyan Medical University, Kufa, Najaf, 54001, Iraq.
Hamdoon A MohammedDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, 51452, Qassim, Saudi Arabia.
Ali K AlbuhadilyDepartment of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Mosleh M AbomughaidDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, 255, 67714, Bisha, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative brain disease due to the progressive accumulation of amyloid protein (Aβ) and neurofibrillary tangles (NFTs). These neuropathological changes trigger excitotoxicity, inflammation, oxidative stress, and neuronal apoptosis. Therefore, targeting Aβ may be operative in the management of AD. However, suppression of normal Aβ, which regulates brain cognitive function, may induce cognitive impairment in healthy individuals. Therefore, this review aims to discuss the potential physiological role of normally present Aβ and neurotoxic Aβ in healthy brains and AD patients, respectively. In addition, in this review, we discussed and explained how targeting neurotoxic Aβ could be effective in the management of AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsBrainHumansNeurofibrillary TanglesOxidative StressAmyloid beta-PeptidesAlzheimer’s diseaseAmyloid proteinExcitotoxicityInflammationNeuronal apoptosisOxidative stress

Identifiers

PMID41014460

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.